Cathepsin K as a target for the treatment of osteoporosis

Bibliography

• TEZUKA K, TEZUKA Y, MAEJIMA A et al: Molecular cloning of a possible cysteine proteinase predomi-nantly expressed in osteoclasts. J. Biol. Chem. (1994) 269(2):1106–1109.
   PubMedGoogle Scholar
• SHI GP, CHAPMAN HA, BHAIRI SM, DELEEUW C, REDDY VY, WEISS SJ: Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit 0C2. FEBS Lett. (1995) 357(2):129–134.
   PubMed Web of Science ®Google Scholar
• BROMME D, OKAMOTO K: Human cathepsin 02, a novel cysteine protease highly expressed in osteoclas-tomas and ovary molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe-Seyler (1995) 376(6)379–384.
   Google Scholar
• INAOKA T, BILBE G, ISHIBASHI O, TEZUKA K, KUMEGAWA M, KOKUBO T: Molecular cloning of human cDNA for cathepsin K - novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. (1995) 206(1):89–96.
   PubMed Web of Science ®Google Scholar
• DRAKE FH, DODDS RA, JAMES IE et al: Cathepsin K, butnot cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. (1996) 271 (20:12511–12516.
   PubMedGoogle Scholar
• ••The paper reports the identification and localisation ofcathepsin K in human osteoclast cells.
   Google Scholar
• KAHN AJ, PARTRIDGE NC: Bone resorption in vivo. In: Bone Volume 2: The Osteoclast (1990:119–140.
   Google Scholar
• BLAIR HC: How the osteoclast degrades bone. BioEssays (1998) 20(10):837–846.
   PubMed Web of Science ®Google Scholar
• KROGER H, REEVE J: Diagnosis of osteoporosis in clinical practice. Ann. Med. (1998) 30(3)278–287.
   Google Scholar
• STEINICHE T: Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS (1995) (Suppl. 50:1–44.
   Google Scholar
• LANE JM, NYDICK M: Osteoporosis: current modes of prevention and treatment. J. Am. Acad. Orthopaed Surg. (1999) 7(0:19–31.
   Google Scholar
• KENNY AM, GALLAGHER JC, PRESTWOOD KM, GRUMAN CA, RAISZ LG: Bone density, bone turnover, and hormone levels in men over age 75.j Gerontol. (Series A Sci. Med. Sci.) (1998) 53 (6):M419–M425.
   Google Scholar
• CASTELOBRANCO C: Management of osteoporosis - an overview. Drugs Aging (1998) 12 (Suppl. 1):25–32.
   Google Scholar
• BOSSARD MJ, TOMASZEK TA, THOMPSON SK et al.: Proteolytic activity of human osteoclast cathepsin K - expression, purification, activation, and substrate identification. J. Biol. Chem. (1996) 271 (20 :12517–12524.
   PubMedGoogle Scholar
• •This paper reports the purification and identification of substrates for cathepsin K.
   Google Scholar
• LITTLEWOOD-EVANS AJ, BILBE G, BOWLER WB et al.:The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. (1997) 57:5386–5390.
   PubMed Web of Science ®Google Scholar
• SUKHOVA GK, SHI G-P, SIMON DI, CHAPMAN HA, LIBBYP: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. (1998) 102(3):576–583.
   Google Scholar
• MCQUENEY MS, AMEGADZIE BY, D'ALESSIO KJ et al.: Autocatalytic activation of human cathepsin K. J. Biol. Chem. (1997) 272(20:13955–13960.
   Google Scholar
• VOTTA BJ, LEVY MA, BADGER A et al.: Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Min. Res. (1997) 12 (9) :1396–1406.
   PubMed Web of Science ®Google Scholar
• ••The report of inhibition of bone resorption in vivo by potentinhibitors of cathepsin K.
   Google Scholar
• GARNERO P, BOREL O, BYRJALSEN I et al.: The collageno-lytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. (1998) 273(48):32347–32352.
   Google Scholar
• KAFIENAH W, BROMME D, BUTTLE DJ, CROUCHER LJ,HOLLANDER AP: Human cathepsin K cleaves native Type I and II collagens at the N-terminal end of the triple helix. Biochem. J. (1998) 331 (Part 3):727–732.
   Google Scholar
• INUI T, ISHIBASHI O, INAOKA T et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. (1997) 272(13) 8109–8112
   Google Scholar
• GELB BD, SHI GP, CHAPMAN HA, DESNICK RJ: Pycnody- sostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 273(5279) :1236–1238.
   Google Scholar
• ••The report links defects in the cathepsin K gene to a raredisease of bone remodelling in humans.
   Google Scholar
• ZHAO B, JANSON CA, AMEGADZIE BY et al.: Crystal structure of human osteoclast cathepsin K complex with E-64. Nature Struct. Biol. (1997) 4(2):109–111.
   PubMedGoogle Scholar
• ••This and the following paper jointly announce the three-dimensional structure of human osteoclast cathepsin K with bound inhibitors.
   Google Scholar
• MCGRATH ME, KLAUS JL, BARNES MG, BROMME D: Crystal structure of human cathepsin K complexed with a potent inhibitor. Nature Struct. Biol. (1997) 4(2):105–109.
   PubMedGoogle Scholar
• ••See annotation for reference 22.
   Google Scholar
• VARUGHESE KI, AHMED FR, CAREY PR et al.: Crystalstructure of a papain-E-64 complex. Biochemistry (1989) 28:1330–1332.
   Google Scholar
• BERGER A, SCHECHTER I: Mapping the active site ofpapain with aid of peptide substrates and inhibitors. Phil. Trans. Roy. Soc. London (1970) B257:249–264.
   Google Scholar
• LALONDE JM, ZHAO B, JANSON CA et al: The crystalstructure of human procathepsin K. Biochemistry (1999) 38(3)862–869.
   Google Scholar
• SIVARAMAN J, LALUMIERE M, MENARD R, CYGLER M: Crystal structure of wild-type human procathepsin K. Protein Sci. (1999) 8(2):283–290.
   PubMed Web of Science ®Google Scholar
• D'ALESSIO KJ, MCQUENEY MS, BRUN KA, ORSINI MJ,DEBOUCK CM: Expression in Escherichia coli, refolding, and purification of human procathepsin K, an osteoclast-specific protease. Protein Exp. Purif (1999) 15(2)213–220.
   Google Scholar
• LALONDE JM, ZHAO B, SMITH WW et al: Use of papain as a model for the structure-based design of cathepsin K inhibitors - crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites. J. Med. Chem. (1998) 41(23):4567–4576.
   Google Scholar
• ••This paper describes the use of the crystal structure ofpapain with inhibitors of cathepsin K bound. The observa-tion of inhibitors bound to the S' sites in papain directly led to the design of novel classes of cathepsin K inhibitors that span the entire active site of the enzyme.
   Google Scholar
• YAMASHITA DS, SMITH WW, ZHAO B et al: Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. (1997) 119(46):11351–11352.
   Google Scholar
• •First report of a novel class of cathepsin K inhibitors which span the active site of the enzyme, as confirmed by x-ray crystallographic studies of the cathepsin K inhibitor complexes.
   Google Scholar
• SCHROEDER E, PHILLIPS C, GARMAN E, HARLOS K, CRAWFORD C: X-ray crystallographic structure of a papain-leupeptin complex. FEBS Lett. (1993) 315:38–42.
   Google Scholar
• DRENTH J, KALK KH, SWEN HM: Binding of chloro-methyl ketone substrate analogues to crystalline papain. Biochemistry (1976) 15:3731–3738.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO A, TOMOO K, DOI Metal: Crystal structure of papain-succinyl-Gln-Val-Val-Ala-Ala-p-nitroanilide complex at 1.7 A resolution: non-covalent binding mode of a common sequence of endogenous thiol protease inhibitors. Biochemistry(1992) 31:11305–11309.
   Google Scholar
• DESJARLAIS RL, YAMASHITA DS, OH HJ et al: Use of x-ray co-crystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K. J. Am. Chem. Soc. (1998) 120(35):9114–9115.
   Google Scholar
• THOMPSON SK, HALBERT SM, BOSSARD M J et al.: Design of potent and selective human cathepsin K inhibitors that span the active site. Proc. Natl. Acad. Sci. USA (1997) 94 (26):14249–14254.
   Google Scholar
• THOMPSON SK, SMITH WW, ZHAO B et al.: Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic. J. Med. Chem. (1998) 41(21)3923–3927.
   Google Scholar
• MARQUIS RW, YAMASHITA DS, RU Y et al.: Conforma-tionally constrained 1,3-diamino ketones - a series of potent inhibitors of the cysteine protease cathepsin K. J. Med. Chem. (1998) 41 (19):3563–3567.
   PubMedGoogle Scholar
• VEBER DF, DRAKE FH, GOWEN M: The new partnership of genomics and chemistry for accelerated drug development. Curr. Opin. Chem. Biol. (1997) 1(2):151–156.
   Google Scholar